Previous Article | Next Article ![]()
Journal of Clinical Microbiology, January 2006, p. 124-131, Vol. 44, No. 1
0095-1137/06/$08.00+0 doi:10.1128/JCM.44.1.124-131.2006
Respiratory Diseases Branch, Division of Bacterial and Mycotic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
Received 12 August 2005/ Returned for modification 20 September 2005/ Accepted 13 October 2005
|
|
|---|
|
|
|---|
1.2 million deaths in children due to pneumonia and meningitis, mostly in developing countries (7). In the United States alone in 2000, S. pneumoniae caused an estimated 17,000 cases of invasive disease in children <5 years of age, including 700 cases of meningitis (1). Contributing to virulence is a capsular polysaccharide, the immunochemistry of which helps to differentiate pneumococci into 90 distinct serotypes (9). However, many of these serotypes are rarely recovered from serious disease, and only about 15 serotypes cause the majority of invasive pneumococcal disease worldwide (7, 23). Although this increases the probability of developing effective vaccines that target the most frequent types, the distribution of serotypes can vary with age, geography, and time, posing greater challenges for vaccine development. The seven-valent pneumococcal conjugate vaccine (PCV7; Prevnar) was licensed for use in the United States in 2000, and a significant decline in invasive pneumococcal disease caused by the vaccine-targeted serotypes has been observed in young children (11, 28). However, little is known about the long-term impact of the vaccine, with early reports indicating some replacement of vaccine serotypes (VT) by non-vaccine types (NVT), both among the nasopharyngeal colonizers and among invasive isolates (6, 11, 28; CDC, unpublished data). Such changes in the seroepidemiology of the organism need to be constantly monitored to evaluate the effect and appropriateness of newer vaccines. Increases in disease caused by previously uncommon NVT could necessitate changes in vaccine composition, emphasizing the need for continued surveillance (15, 22).
Currently, serotype distribution is monitored by culture of the organism followed by serological determination of the capsular type by the standard capsular test (9, 16). The high cost of antisera, subjectivity in interpretation, and technical expertise requirements are serious drawbacks of the system. The development of PCR-based serotyping systems has the potential to overcome some of the difficulties associated with serologic testing (3, 13). In addition, the development of PCR-based assays for direct detection of select serotypes from clinical specimens could be a valuable aid in surveillance, particularly in situations where culture is insensitive (14, 25). Production of capsule is largely controlled by capsular polysaccharide synthesis genes located at the cps locus, typically with the same general genetic organization and flanked by the conserved dexB and aliA genes (21). The first four genes are conserved in almost all serotypes, while the central parts of the loci contain the serotype-specific genes that serve as the basis for differentiation of pneumococci by PCR-based approaches. Though these molecular approaches to serotyping appear promising, the existing systems identify a limited number of serotypes (3, 13, 14, 24) and need to be expanded to establish a more comprehensive approach for routine surveillance. Recently, an approach relying upon amplification of the entire cps locus, followed by restriction fragment length polymorphism analysis, was assessed (2). Although this scheme shows promise, we prefer an approach that does not include segments of the cps locus that are highly conserved between serotypes, but instead relies upon upon short sequences specific to individual serotypes or serogroups. The sequences of thecps loci from all of the known90pneumococcal serotypes have been completed recently (http://www.sanger.ac.uk/Projects/S_pneumoniae/CPS/), providing an opportunity to develop a simple sequence-based scheme for identifying most commonly occurring serotypes.
The Active Bacterial Core surveillance (ABCs), part of the Centers for Disease Control and Prevention's (CDC) Emerging Infections Program, has conducted active, population-based, laboratory-based surveillance for invasive pneumococcal disease since 1995 (4). The surveillance program currently includes nine sites (as of 2003) with over 25,000,000 persons under surveillance (http://www.cdc.gov/ncidod/dbmd/abcs/). Over 3,000 invasive ABCs pneumococcal isolates are currently received annually at the CDC Streptococcus Laboratory for serotype determination. We used serotype distribution data from the 2002-to-2003 ABCs to develop a simple, cost-effective, multiplex PCR-based approach for deducing serotypes within large sets of isolates.
|
|
|---|
Serotyping. Preliminary serotyping (to detect pools) was performed by the latex agglutination test with capsular typing sera prepared at the CDC. All serotypes were confirmed using the Quellung reaction.
Molecular capsular typing. (i) Oligonucleotide primers. Twenty-nine primer pairs were designed to target serotypes 1, 3, 4, 5, 6A/B, 7F, 7C, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B/C, 16F, 17F, 18, 19A, 19F, 20, 22F, 23F, 31, 33, 34, 35B, 35F, and 38. A primer pair (primers cpsA-f and cpsA-r) was also included as an internal control targeting the cpsA locus found in all pneumococci (17). To design primers, all available relevant cps gene sequences were aligned (MegAlign) and primers were selected using the PrimerSelect program of DNASTAR version 5. The primers were designed to target the following genes (serotypes are indicated in parentheses): cap1H (1), cap3C (3), wzy (4, 33F, and 18), wxy (5), wcip (6), cap8G (8), cps9VL (9V), cps14H (14), cps19aK (19A), cps19fI (19F), and cps23fG (23F). Although functional annotations were not available for the rest of the serotypes for which primers were designed, many of these sequences showed homology to other pneumococcal cps operon genes (e.g., cps9VI with 11A and 9V; cps6bS with 17F, 6A, and 6B; cps4H with serotypes 4 and 20; cps19fG with 19F and 35F; cps19cS with 22F and 19C; and cps6bI with 34, 6A, and 6B). Every primer pair was compared to all other cps sequences both at http://www.sanger.ac.uk/Projects/S_pneumoniae/CPS/ and at www.ncbi.nlm.nih.gov to determine the specificity and cross-reactivity with all other pneumococci. All primers were synthesized at the Biotechnology Core Facility Branch, CDC. The primer designations, sequences, and product sizes are listed in Table 1.
|
View this table: [in a new window] |
TABLE 1. Oligonucleotide primers used in this study
|
![]() View larger version (32K): [in a new window] |
FIG. 1. Schematic approach to molecular capsular typing, indicating the seven reactions and the serotypes detected in each reaction.
|
(iv) PCRs. The PCRs were performed in 25-µl volumes, with each reaction mixture containing the following: 1x PCR buffer (20 mM Tris-HCl, pH 8.0, 100 mM KCl, 0.1 mM EDTA, 1 M dithiothreitol, 0.5% Tween 20, 0.5% Nonidet P-40; Promega Inc., Madison, Wis.), 200 µM of each deoxynucleoside triphosphate (New England Biolabs, Beverly, MA), 2.5 mM of MgCl2, 2.0 U of Taq DNA polymerase (Promega Inc.), and primers with concentrations as specified in Table 2. Crude extract (2.5 µl) was used as the DNA template for each PCR. Thermal cycling was performed in Perkin-Elmer GeneAmp PCR system 2700 (Applied Biosystems) under the following conditions: 94°C for 4 min followed by 30 amplification cycles of 94°C for 45 s, 54°C for 45 s, and 65°C for 2 min 30 s.
|
View this table: [in a new window] |
TABLE 2. Primer concentrations in seven multiplex PCRa
|
(vi) Pyrosequencing assay. All isolates identified as serogroup 6 by multiplex PCR were further differentiated as types 6A or 6B by a pyrosequencing assay designed to detect the single nucleotide polymorphism at codon 195 of the cps locus wciP gene as described previously (19). Pyrosequencing is a real-time DNA sequencing technique for generating short reads rapidly and inexpensively (24).
|
|
|---|
![]() View larger version (102K): [in a new window] |
FIG. 2. Representative multiplex reactions. The serotypes of four strains tested for each of eight different multiplex formulations are shown below their respective lanes.
|
|
View this table: [in a new window] |
TABLE 3. Serotyping results deduced by sequential multiplex PCR for 421 randomly chosen invasive pneumococcal isolates
|
For 40.9% (172/421) of the isolates, the multiplex scheme narrowed the results to 1 of 11 serotype sets that included a major serotype plus 1 to 3 minor serotypes that were primarily within the same serogroup. For all of these except serogroup 6, only one serotype of the set is relatively common among ABCs, with the additional serotypes (in parentheses in Table 3) rare among current ABCs pneumococcal isolates (accounting for only 0 to 0.2% of isolates among year 2003 isolates; n = 2,798). If potential cross-reactions were disregarded, the original targeted serotypes would have been correctly predicted among 95.2% of the isolates.
The 20 (4.7%) isolates for which serotypes could not be deduced by the system included 10 serotypes not included in the multiplex reaction scheme (Table 3). Three isolates that were repeatedly not amplified by specific primer sets as well as the internal control corresponded to two nontypeable isolates and a single type 9V isolate from original conventional serotyping. All three of these isolates were subsequently retested by conventional serotyping and found to be nonserotypeable.
Since the first three reactions in the sequential multiplex scheme are designed to cover the predominant serotypes within the United States, we attempted to make the system expeditious by performing PCR for the first three reactions simultaneously on all isolates. This allowed us to obtain results for 62.5% (263/421) of the isolates within the first three reactions and would theoretically identify
68% of the ABCs isolates obtained during 2002 to 2003.
Pyrosequencing. The multiplex assay identified 35 of the 421 isolates as serogroup 6. Therefore, 14 µl of the amplified product obtained through reaction 1 was used for the pyrosequencing assay as described previously. Pyrosequencing accurately identified the serotype of these isolates as serotypes 6A (n = 19) and 6B (n = 16).
Modification of primer combinations. While the seven reactions described above were designed to cover most of the predominant serotypes reported in the United States, reactions 1 and 2 were altered based on the prevalence data in other geographic regions (Asia and Africa) to include primers targeting serotypes 1, 5, 6A/B, 7F, 14, 19A, 19F, and 23F. These altered reactions (reaction 1 contained primers for serotypes 19A, 1, 6, and 19F and reaction 2 included serotypes 14, 5, 7F, and 23F) were a combination of serotypes different from that in the original sequential PCR scheme. A 4% gel was used to detect these products (example shown in Fig. 2).
|
|
|---|
Our study indicates that cps genes can be targeted to efficiently and reliably determine pneumococcal serotypes. The primers cpsA-f and cpsA-r were included in all reactions as an internal control targeting the cpsA gene, a highly conserved gene present in all pneumococci (18). This locus was amplified in all the strains characterized, except in four strains which were also nontypeable by conventional serotyping (three nontypeable and one type 9V rendered nontypeable on repeat capsular testing). The absence of amplification among such rough strains has been reported previously (3) and is probably due to the absence of the cps locus or cps sequence alterations. Seventeen of the primers in this sequential multiplex PCR system were found to be highly specifically associated with no cross-reactivity. These primers could reliably detect all isolates tested of corresponding types. This observation is particularly important as the primer designs for many serotypes have been based on the sequence information obtained from a single isolate. (All serotype sequences available at www.sangers.ac.uk are based upon one isolate of the corresponding serotype.) We did not find evidence suggesting that the genetic variability between different strains of the same serotype may affect its serotype determination by a PCR-based approach as suggested previously (29). Although we did analyze genetically diverse sets of isolates for several serotypes (data not shown), it is still possible that strains from other countries of corresponding serotypes could present confounding cps region sequence diversity. We targeted central cps targets that were most apt to be serotype specific based upon current understanding of the organization of cps loci and based upon our own exhaustive screening of primers against all known cps locus sequences. However, not all primers included in these seven reactions were entirely specific. For example, the sequence homology between serotypes within serogroups 18 and 6 prevented the development of type-specific primers. Similarly, cross-reactivity between additional targeted serotypes (7F, 7C, 9V, 38, 11A, 12F, 22F, 33F, and 35F) and other serotypes is a problem. Fortunately, strains of the cross-reacting serotypes are rarely causes of serious invasive disease in the United States (7). Nonetheless, conventional serotyping will have to be performed to differentiate such isolates, although the procedure will be greatly streamlined with the knowledge that after the major multiplex reaction serotype, there are only one to three additional serotypes to screen. The PCR assays described so far have reported similar limitations in developing type specific primers among cross-reacting serotypes (3, 13, 25). The difference between serotypes 6A and 6B has been correlated to a single nonsynonymous substitution in the putative rhamnosyl transferase gene (wciP) (17), making it impossible to serotype such strains by a PCR-based approach. The pyrosequencing assay is highly reliable and cost-effective (19) and could differentiate all 35 isolates of serogroup 6. Though pyrosequencing may not be readily available at all centers, it is of potential use in resolving other sets of cross-reacting serotypes, when genetic polymorphisms specific to each serotype become available.
The sequential multiplex PCR assay described here is reliable and expeditious when the first three reactions are performed simultaneously for all isolates. The first three reactions detected 54.3% of the isolates included in this study. Since these reactions include 12 primer pairs that target the predominant serotypes associated with invasive disease in the United States, they would detect
68% of all isolates obtained through the ABCs surveillance (1999 to 2003). Similarly, the serotype prevalence data obtained through other surveillance studies also indicate that these three reactions would help to detect the predominant serotypes seen in children <5 years of age within the United States (11). Another recent study of S. pneumoniae infection in neonates also shows that SGT 19, 9, and 3 account for
60% of all invasive neonatal infections (10). Therefore, this schematic approach is particularly helpful to maximize detection of predominant types using a limited number of multiplex reactions. However, it is essential to consider the changing epidemiology and the increase in certain non-vaccine types such as serogroups 15 and 33, which are reported to have increased in children <5 years of age since the introduction of PCV7 (11). Though our scheme does not allow the detection of these serotypes within the first three reactions, both of these serogroups are represented in the subsequent reactions 4 and 5 and will be detected using this system. Also, we demonstrated the flexibility of this system to adapt to new surveillance data or areas through the usage of two altered reaction formulations targeting the predominant serotypes in Asia and Africa (7). This system can also be useful in regions where no serotype data are available and could serve as a starting point to determine serotype frequencies.
There were eight instances where discrepancies between the multiplex PCR scheme and original conventional serotyping results were observed. In these instances, the PCR-based results proved to be accurate. While these discrepant results are difficult to explain, repeat serotyping has resulted in correction of serotype data at our center (5). Such errors have been reported by other reference laboratories (12) and emphasize the need for more reliable serotyping techniques. These errors/discrepancies also highlight the subjectivity of conventional serotyping, especially when differentiating the strains within the same serogroup. Serotypes 23F/23B, 35F/35B, and 7F/7C are easily resolved using our multiplex PCR scheme, with no subjectivity in interpretation (although the 7F and 7C reactions cross-react with the rare serotypes 7A and 7B, respectively).
This multiplex PCR system can be easily introduced in most clinical laboratories. The use of crude DNA extracts obviates the need for more specialized template preparation protocols and detects the most common serotypes using a minimal number of reactions, and products can be detected easily by gel electrophoresis. We have found that we can readily assign results to 96 isolates in a single day. We envision that most reference laboratories will in the future adopt a molecular approach to capsular typing. For example, the primers used in this system could potentially be used in the development of a multiplex oligo-capture system that relies upon a universal pair of primers for "long PCR" of all cps operons. We are currently investigating the feasibility of such an oligo-capture system.
The multiplex PCR system described in this work is cost-effective. Accounting for the fact that we produce our own typing sera, our estimated average cost per strain by a combination of latex agglutination (for pools) and Quellung reaction is $5, and this increases up to $10.98 for nontypeable strains. The average cost per isolate using commercially available antisera could be as high as $28 (3). The cost per isolate when characterized by multiplex PCR would be as low as $2.28 if a minimum of three reactions are performed and up to $5.32 if all seven reactions are used. Our multiplex PCR system is designed to detect more than 60% of the strains in our surveillance, within the three reactions, dramatically reducing the costs compared to conventional serotyping. It must be mentioned that a recently described flow cytometric, multiplexed serologic approach appears to be very cost-effective in that it greatly reduces labor and dependence upon typing antisera (29). This methodology also has the capability to detect secondary serotypes within mixed cultures (29), which cannot be readily accomplished using a multiplex PCR approach. Another potential weakness of DNA-based approaches is the potential to assign serotypes to strains with defective cps operons, although such isolates are rarely recovered from invasive infections.
Although our multiplex PCR system identifies or greatly streamlines identification of the majority of predominant serotypes circulating within the United States, the number of primers will need to be increased for a comprehensive system. We are confident that the work we present here will serve as an excellent starting point for the development of a simple system utilizing a single cps locus PCR product (http://www.sanger.ac.uk/Projects/S_pneumoniae/CPS/) (2) and specific oligonucleotides for the identification of all pneumococcal serotypes.
We sincerely thank the Active Bacterial Core surveillance personnel for data collection, and Cynthia Whitney for useful initial discussion concerning this project. We gratefully acknowledge the dedicated laboratory support of Tim Bailiff, Alma Ruth Franklin, Delois Jackson, Zhongya Li, Saundra Mathis, Varja Sakota, and Shantia Williams. We also thank Terry Thompson for verifying some serotyping results and providing cost estimates.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»